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Hypersensitivity pneumonitis (HP) is an interstitial lung disease due to a combined type III and IV reaction with a
granulomatous inflammation, caused by cytotoxic delayed hypersensitivity lymphocytes, in a Th1/Th17 milieu,
chaperoned by a deficient suppressor function of T regulatory cells. Skewing toward a Th2 phenotype is reported
for chronic HP. Phenotypic expression and severity depends on environmental and/or host genetic and immune
co-factors. The wide spectrum of causative antigens is continuously up-dated with new sources of airborne organic
particles and drug-induced HP. The diagnosis requires a detailed history, measurement of environmental exposure,
pulmonary function tests, imaging, detection of serum specific antibodies, broncho-alveolar lavage, antigen-induced
lymphocyte proliferation, environmental or laboratory-controlled inhalation challenge and lung biopsy. Complete
antigen avoidance is the best therapeutic measure, although very difficult to achieve in some cases. Systemic
steroids are of value for subacute and chronic forms of HP, but do not influence long term outcome. Manipulation
of the immune response in HP holds future promise.
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Hypersensitivity pneumonitis (HP) is an interstitial lung
disease (ILD) due to a combined type III and IV reaction
with a granulomatous inflammation. The formation of
immune complexes with IgG was considered to be a
central part of pathogenesis. The current view is that HP
is caused by cytotoxic delayed hypersensitivity lympho-
cytes, in a Th1/Th17 milieu (Figure 1).
Although many individuals are exposed to environmen-
tal antigens known to induce HP only approximately
5–15% will develop the disease [1]. The low prevalence
rate suggests that the phenotypic expression of the disease
depends on environmental co-factors, such as viruses [2,3]
and/or host genetic and immune co-factors, which also
promote considerable variability in disease severity and
response to treatment. The mechanisms of progression to
a chronic form remain unclear. For chronic HP a skewing
toward a Th2 phenotype was described [4,5].
HP can occur in an occupational setting or after
home exposure, following inhalation of organic anti-
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distribution, and reproduction in any mediumlow-molecular-weight chemicals or Mycobacterium avium-
intracellulare complex organisms. As a non-inhalant
variant HP can appear as a manifestation of drug-induced
lung disease.Recently described entities
There is a wide spectrum of causative antigens for HP, and
new sources of airborne organic particles are continually
being recognized. Recently described are the trombone
player and Chacinero’s lung [6,7], HP associated with
catechin-rich green tea extracts [8], use of ultrasonic
misting fountains at home [9], Shiitake mushroom spores
[10], mosquito-coil smoke [11] medium-density fiberboard
[12] or cash handling [13].
Reports on drug-induced HP are increasing in frequency,
and interestingly some of these drugs were previously
proposed as potential therapeutic agents for HP. Most
of the recent reported drugs inducing HP are immune
modulators used to treat neoplastic [14,15] and connective
tissue diseases [16] or transplant recipients [17,18].Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Pathogenenic mechanisms in hypersensivity pneumonitis.
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therapy
a. The role of antigen-presenting cells
Through their key role in antigen presentation
dendritic cells (DCs) are key players in the
development of T cell–dependent adaptive immune
responses. In an animal model of HP expression of
stem cell antigen CD34 by lung mucosal DCs was
required for migration of DCs from the lung to the
lymph nodes in response to the HP antigen
Saccharopolyspora rectivirgula. Loss of CD34
protected from development of HP. Since the CD34
molecule seems to play a role in the transition from a
primary to a chronic T-cell response in HP and its
deletion in mice did not associate any significant
defect it might represent an appealing future
therapeutic target in HP [19]. Another requirement
for an efficient antigen presenting cell (APC) is the
presence of adjuvant activity of the microbial
components. IL-1 level is increased in the broncho-
alveolar lavage fluid (BALF) of HP patients [20]. In
mice models IL-1β demonstrated adjuvant properties
[21], and was necessary for the production of
antibodies against T-cell dependent antigens [22]. IL-
1β acts directly on memory T Cells [21] and on CD4T cells to enhance their antigen driven expansion and
differentiation, especially into IL-17 and IL-4
producing cells [23]. Viral infection can also promote
maturation of DCs [3].
HP is characterized by an influx of activated T cells
to the lung, in which the CD28/B7 co-stimulatory
signals from the APCs are essential for T cell
activation and the outcome of the inflammatory
response. The alveolar macrophages isolated from
patients with HP have elevated levels of the
co-stimulatory molecules CD80 and CD86 [24],
while blockade of the CD80/86–CD28 co-stimulation
pathway confers protection from experimental
HP [25].
b. The role of T-cells
Interferon gamma [IFN-γ] plays a critical role in the
formation of granuloma in HP, while TLR9 appears
also required [26,27]. Overproduction of other Th1
cytokines, IL-12 and IL-18 by BALF macrophages
was reported [28]. Other studies using animal models
have suggested that HP is a Th17 disease calling into
question the role of Th1 skewed response [29].
Genetic deletion and immunoneutralization of IL-17
protects against the development of mouse HP [30].
TLR9 is required for the development of Th17-
mediated granulomatous inflammation [31]. Within
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role in the development and severity of HP via its
role in IL-17A production [32]. A recent study
showed that initially IFN-γ production is dependent
on IL-18 and the transcription factor T-bet, however
as the disease continues IFN-γ production becomes
IL-18-independent and partially T-bet dependent. In
animal models for HP T-bet deficiency leads to a
more severe disease characterized by an exacerbated
Th17 cell response, decreased Th1 cell response, and
increased collagen production in the lung. T-bet-
mediated protection does not appear to be due to the
development of a protective Th1 response because
shifting the balance from a Th17 predominant
response to a Th1 response by inhibition of IL-6 also
results in lung pathology. Thus, both Th1 and Th17
cells can be pathogenic in HP, but they have
divergent roles in the disease process [33].
In a mouse model of HP that progresses to lung
fibrosis upon repeated exposure to Bacillus subtilis,
γδ T cells expand in the lung and inhibit collagen
deposition. In this model a subset of γδ cells are the
predominant source of the Th17 cytokine IL-22.
Blockade of expression of IL-22 accelerated lung
fibrosis, whereas administration of recombinant IL-
22 inhibited lung fibrosis. Moreover, the presence of
protective γδ T cells and IL-22 diminished
recruitment of CD4+ T cells to lung [34]. In the
same model In the absence of IL-17 receptor
signaling mice had delayed clearance of Bacillus
subtilis with increased lung inflammation and
fibrosis. Although IL-17A was predominantly
expressed by γδ T cells, a compensatory increase in
IL-17A expression by CD4[+] T cells was seen in the
absence of γδ T cells that resulted in similar levels of
IL-17A in the lungs in TCR δ deficient mice [35].
Galectin-9 was also proven to expand the
immunosupressive macrophages and ameliorate
experimental Th1/Th17 cell-mediated HP [36].
Loss of T-regulatory cells (Tregs) control over the
immune response is essential for the impaired
immune tolerance in HP. Experimental HP induced
in CD4 + CD25+ Tregs-depleted mice showed a
protective role of Tregs via suppression of IFN-γ
production by T cells [37]. In humans T regs from
BALF and blood obtained from asymptomatic
exposed subjects had lower suppressive function
compared to normal subjects, while Tregs from HP
patients were totally nonfunctional and unable to
suppress proliferation. Partially preserved Tregs
suppressive function may explain antigen tolerance in
asymptomatic exposed subjects. Defective Tregs
function is potentially caused by increased IL-17
production since low levels of IL-17 were detected insera and BALF from both normal and asymptomatic
individuals, whereas measurable levels were found in
HP patients [38].
c. The role of inflammation and apoptosis
Macrophages and neutrophils are activated in HP via
Fc-γ receptors and accumulate in involved tissues
[39]. Activated neutrophils loaded with matrix
metalloproteinase 9 and collagenase-2 were found to
play role in lung damage and fibrotic response in
chronic HP [40]. In addition, angiostatic and
angiogenic chemokines promote the development of
fibrosis [41,42].
Increased apoptosis in non-hematopoietic cells and
Gr-1+ granulocytes of the lungs promotes HP by
enhancing maturation and chemokine production of
CD11c + DC [43]. Immunohistochemical studies of
surgical lung specimens from HP patients showed
up-regulation on epithelial cells of Fas, Fas ligand,
p53 and p21 expression in usual interstitial
pneumonia (UIP)-like lesions compared with
nonspecific interstitial pneumonia (NSIP)-like lesions.
The expression of p53 and p21 was also increased in
fibrotic NSIP [fNSIP]-like lesions compared with
normal lung tissues [44].
Diagnostic procedures
At the current time, there is no single diagnostic single
procedure or biomarker to confirm the diagnosis of HP.
The diagnosis requires a detailed and careful history that
would include social, environmental, and occupational sta-
tus, measurement of environmental exposure, pulmonary
function tests, imaging, detection of serum specific anti-
bodies, examination of BALF, antigen-induced lymphocyte
proliferation, environmental or laboratory-controlled in-
halation challenge with the suspected antigen and lung
biopsy (Figure 2). Major and minor diagnostic criteria are
described [45]. A sentinel case should prompt to the iden-
tification of exposed subjects who might develop the
disease. Improvement of symptoms away from exposure
and/or a rapid response to oral steroids should heighten
the awareness of HP.
a. Environmental exposure
Recognition of the exposure to antigen is critical for
diagnosis and avoidance of exposure. The detection
of a single causative antigen for HP can prove very
difficult since usually subjects are exposed to several
inhalation antigens.
For bird fancier’s lung (BFL) a variety of indirect and/
or unrecognized exposures to birds were described
including pigeons raised by neighbors, a flock of
pigeons and/or wild birds in parks, shrines and
railway stations [46,47]. In addition avian antigen was
reported to persist in the patient’s house 6 months
Figure 2 Management of hypersensivity pneumonitis.
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cleanup [48].
Measuring the smallest amount of causative antigen
in patient’s environment is crucial. For BFL the
methods used to detect the avian antigen in dust
samples (inhibition ELISA) [48], or in dust and air
samples (direct competitive ELISA) [49], were not
sensitive enough to measure a small amount of
antigen. Kuramochi et al. recently described an
antigen-capture ELISA with signal amplification
using catalyzed reporter deposition for measuring
small amounts of indoor and outdoor avian antigen
[50]. Molecular methods using quantitative
polymerase-chain reaction might offer advantages
over culture and optical methods for estimating low
level exposure to microbiological agents such as
fungi [51-53].
Evaluation of personal exposure at work should
include details on current and previous occupations,
work processes, type of exposure and environmental
factors. In farmer’s lung disease (FLD) both
environmental factors and agricultural practices can
independently modify concentrations in hay of
microorganisms potentially responsible for HP. Bad
climatic conditions of harvest, high-density hay-
packing modes, (especially round balls) and altitude
(700–900 m) were associated with high
concentrations of microorganisms in hay [54].
Worksite assessment together with an industrial
hygienist is recommended.b. Imaging
High resolution computed tomography (HRCT) is
the “gold-standard” imaging method for HP.
Although the individual HRCT findings are
nonspecific, their combination coupled with their
distribution can narrow the differential diagnosis.
There are corresponding findings for each of the
clinical phases of HP, although there is some overlap
between the phases. Typical findings include
confluent opacities in the acute phase, centrilobular
nodules, areas of ground-glass attenuation, a mosaic
perfusion pattern, air trapping in the subacute phase
and subpleural irregular linear opacities with
associated architectural distortion in the chronic
phase. The reticulation HP can be random or have a
predominantly subpleural and peri-bronchovascular
distribution. Honeycombing may be present. In the
acute and subacute phases, the disease is
predominantly in the lower lungs, whereas in chronic
HP the findings are predominant in the mid to
upper lungs [55].
HRCT can be normal, especially when scans are
obtained at greater intervals in relation to
exposure [56].
c. Serum specific antibodies
The finding of circulating antibodies against the
putative offending antigens is useful for diagnosis.
However, it is important to emphasize that exposed
individuals may have antibodies without disease, and
some patients may give false negative results [57],
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techniques may be insensitive to detect low levels of
antibodies. Enzyme immunoassays (EIA) have
successfully replaced in many cases the precipitation
techniques. However, standardising EIA proves
challenging because of the difficulty in obtaining
stable solid phases from a huge variety of
heterogeneous antigenic sources. Novel detection
methods such as the automated fluorimetric EIA
(Streptavidin ImmunoCAP) have been advocated for
measuring antibodies elicited by protein antigens that
are not commercially available [58]. The method can
also differentiate with a specificity of 97% and a
sensitivity of 90% between IgG antibodies specific for
feather duvet lung (FDL) and IgG specific for BFL
[59]. The use of recombinant antigens was reported
for serological diagnosis of metalworking fluid-
associated HP (MWF-HP) [60].
Choosing the relevant antigens for the EIA detection
panel is essential. Out of the three Eurotium
amstelodami antigens extracts tested (ascospore,
conidia and hyphae), the cutoffs showed the highest
sensitivity and specificity for the ascospore antigen,
thus its measurement improves significantly the
serological diagnosis of FLD [61]. Instead of using a
standard kit the selection of antigens to be tested is
better determined locally according to the prevalent
antigens [62].
The sensitivity and specificity of serologic tests
varies with the clinical form of the disease. For
example, in acute BFL antibodies titers were
markedly increased and showed high sensitivity and
specificity ranging from 75–100%, while in the
chronic form antibody reactivity was slightly
increased, showing a sensitivity of 27–73% and
specificity of 45–100% [63].
The discriminative value of serologic tests between
exposure and disease is controversial, and might vary
with the putative antigen and with the detection
method. One study showed no difference between HP
patients and exposed controls for serum
concentrations of IgG against moulds or mammals
antigens [64]. However, in the same study IgG against
bird antigens were significantly higher in HP patients
versus exposed controls. In contrast, an older study
using an immunoprecipitation method reported an
incidence of 40% for specific IgG in asymptomatic bird
keepers [65]. A threshold was proposed to discriminate
between exposed controls and MWF-HP, but this
remains to be proven for other antigens [66]. For
antibodies against molds electrosyneresis on cellulose
acetate was suggested to discriminate best between
active HP and other types of ILD [67], or between
patients and healthy exposed farmers [68].Whether antibodies measured in healthy exposed
controls further predispose to full blown HP remains
to be proven in longitudinal studies. It has been
shown that patients who were exposed to avian
inhalation antigens in their childhood or during later
life may develop FDL after exposure to bedding filled
with goose feathers [69].
d. Bronchoalveolar lavage fluid examination
A normal BALF excludes HP diagnosis [70]. On the
other hand asymptomatic exposed subjects can have
a lymphocytic alveolitis, which is not part of a
subclinical form of disease as proved by the long-
term follow up of these individuals [65].
BALF examination in HP usually shows a
lymphocytic alveolitis, classically with an increase of
CD8+ lymphocytes and inversion of the CD4/CD8
ratio, associated with moderate neutrophilia, and
mild eosinophilia and mastocytosis [70]. An increase
in plasma cells, signs of macrophage and T cell
activation, foamy macrophages or with cockade-like
structures in their cytoplasm were also described
[71-74]. Acute episodes of HP are associated with an
influx of neutrophils lasting for up to 1 week. After
this period, the cellular profile of the BALF returns
to lymphocytic alveolitis.
Absence of a low CD4/CD8 ratio should not exclude
HP diagnosis, since a recent study reported a low
ratio in only 34% cases. The CD4/CD8 ratio was not
different between forms, etiologies of HP, and time
elapsed since last antigen exposure, but was higher in
women [75].
Immunophenotyping of BALF cells might improve
diagnostic accuracy and measure disease activity.
Thus, for HP patients a higher proportion of CD8 +
T-cytotoxic cells was described. For all ILD a positive
association was found between the density of type I
alveolar epithelial cells and FVC [76]. Increased
expression of CD69, VLA-1 and decreased expression
of CD28 on CD4+ cells and increased expression of
HLA-DR on CD8+ cells was correlated with the
extent of parenchymal involvement and decreased
DLCO values [77].
The detection of fungal DNA in BALF cell pellets
might prove an useful diagnostic tool [78]. Proteome
analysis of BALF in chronic HP pinpointed several
biomarkers which might distinguish between the UIP
and fNSIP patterns [79].
e. Antigen-induced lymphocyte proliferation
Antigen-induced lymphocyte proliferation can aid
the diagnosis of insidious forms of HP. In FDL
specific antibodies against avian antigens were
positive only in the acute form of the disease, while
antigen-induced lymphocyte proliferation in
peripheral blood or BALF cells was positive in all the
Agache and Rogozea Clinical and Translational Allergy 2013, 3:5 Page 6 of 10
http://www.ctajournal.com/content/3/1/5patients [80]. In chronic BFL specific antibodies
against pigeon or budgerigar dropping extracts were
positive in 87% of the recurrent form and 35% of the
insidious cases, while antigen-induced lymphocyte
proliferation was positive in more than 90% of both
groups [46]. Antigen-induced lymphocyte
proliferation is also useful in differentiating subjects
with HP from asymptomatic exposure [81,82].
f. Environmental or laboratory-controlled inhalation
challenge
The use of inhalation challenge tests for HP diagnosis
is hampered by the lack of standardization for the
inhalation protocol and for defining a positive
response.
The reported diagnostic sensitivity of the test for BFL
is 92%, while specificity reaches 100% [83]. Inhalation
challenge with avian dropping extracts in chronic
BFL evaluated as positive or probable all patients
further proven by a combination of diagnostic
criteria, whereas all control subjects were evaluated
as negative [84].
g. Lung biopsies
Establishing the diagnosis of HP in the absence of
lung biopsy is challenging and is heavily dependent
on identification of a specific antigenic exposure.
Examination of surgical lung biopsies in HP usually
shows an airway-centered chronic interstitial
pneumonia, a lymphocyte-rich chronic bronchiolitis,
and poorly formed non-necrotizing granulomas
distributed mainly within the peribronchiolar
interstitium. Variable degrees of peribronchiolar
fibrosis and hyperplasia of the bronchiolar
epithelium are described. In some patients,
granulomatous inflammation may be lacking,
resulting in a histological appearance resembling
NSIP [85]. Increased fibrin deposition and
neutrophilic infiltrate suggests either acute HP or
exacerbation of chronic HP [86]. Late-stage fibrotic
HP closely mimics UIP or fNSIP, while cellular NSIP
or organizing pneumonia patterns are rarely found
[85,87]. Centrilobular fibrosis, often connecting to
the perilobular areas in the appearance of “bridging
fibrosis” in association with an UIP pattern is also
suggestive for chronic HP [88]. Acute exacerbations
of HP appear as diffuse alveolar damage or
bronchiolitis obliterans organizing pneumonia
superimposed upon the fibrosing interstitial
pneumonia [89].
Immunohistochemical demonstration of the
causative antigen in the lung tissue might prove
valuable. For BFL immunohistochemistry using a
polyclonal antibody against pigeon serum showed a
predominant cytoplasmic immunostaining in
multinucleated giant cells and histiocytes from lunggranulomas [90]. Immunohistochemistry can
identify microgranulomas in chronic HP following
detection of cathepsin-K, a potent cysteine
protease expressed at high levels in activated
macrophages [91].Measuring HP activity
An increase in alveolar NO following re-exposure in HP
was described in a case-report [92] and deserves further
investigation as a measure of disease activity in HP.
As biomarkers reflecting the lung injury/regeneration
cycle substances derived from type II pneumocytes are po-
tential candidates to monitor disease activity. Serum Krebs
von den Lungen-6 mucin (KL-6) is elevated in 70–100%
of patients with various ILDs, including HP [93]. Increase
in serum level of surfactant protein D [SP-D] was also
reported [94]. In a long term follow-up of a patient with
BFL after removal of antigen exposure SP-D and KL-6
returned to normal in 8 and 18 months respectively, while
DLCO improved slowly in parallel [95].
Prognostic factors
The long-term outcome (mean 14 years) of pulmonary
function was evaluated in FLD patients compared to con-
trol farmers matched by age, sex, and smoking habits. The
mean DLCO was on average with 12% lower in patients
compared to controls. The mean maximum expiratory
flow at 50% of vital capacity was also lower and airway
obstruction was more common. Patients with recurrent
episodes had a significantly lower mean DLCO compared
to those experiencing only a single episode [96].
High BALF neutrophil count was documented to be a
sign of irreversible lung fibrosis [32]. CA 15–3 was
demonstrated equally sensitive and specific to KL-6 in
terms of differentiating between ILDs with and without
fibrosis [97].
As for other ILD the presence of established fibrosis,
especially when associated with architectural distortion
in the form of honeycombing, is associated with shorter
survivals [98]. HRCT patterns, in particular, severity of
traction bronchiectasis and extent of honeycombing are
superior to FEV1, FVC and DLCO for predicting mortal-
ity in patients with chronic HP [99]. The prognosis of
fNSIP pattern tends to be better compared to the UIP
pattern [87]. Pulmonary hypertension is not rare in
chronic HP and significantly impacts survival [100].
Patients with low total lung capacity and DLCO, low
lymphocyte levels in BALF and a UIP-like pattern at the
time of diagnosis have increased risk for acute exacerba-
tions of chronic HP [101].
The 10.6% reported prevalence of lung cancer in
chronic HP is similar to idiopathic pulmonary fibrosis
(IPF). Tumors were located adjacent to honeycombing
lesions, bullae or in the relatively normal lung [102].
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Complete antigen avoidance is the essential step in the
management of HP (Figure 2). The majority of cases im-
prove or heal, but some evolve to a chronic form prob-
ably due to persistence of exposure at an undetectable
level in association with genetic and immunologic fac-
tors. In a long term follow-up of patients with BFL there
was persistence of sensitized lymphocytes and antibody
production in the respiratory tract up to 5 years [103].
Systemic corticosteroids are recommended for subacute
and chronic forms of HP. The usual regimen consists of
initial high doses followed by gradual tapering. Treatment
continues until no further improvement in physiologic ab-
normalities is observed. The use of inhaled corticosteroids
is anecdotal.
In a cohort of Danish children with HP high dose intra-
venous methylprednisolone had no clinical impact, since
both lung function and DLCO remained subnormal [104].
In adults with FLD corticosteroid treatment improved
quickly lung function compared to placebo, but after
5 years there was no difference between the two groups.
An increased incidence of recurrent attacks, without
reaching statistical significance, was observed in the
corticosteroid group [105]. In adults with chronic HP
prednisolone was effective in only 58% of cases [106], thus
for progressive chronic HP immunosuppressants may be
necessary.
Although in vitro studies have shown promise for tha-
lidomide [107], pentoxifylline [108], low-dose long-term
macrolides [109], and cyclosporine [110], no controlled
clinical trials have been performed. In addition, several
recent reports on HP induced by thalidomide-like drugs
such as lenalidomide [111,112], roxytromycin [113],
cyclosporin [114] and cyclosporin-like drugs such as
everolimus [17] and sirolimus [18] preclude the use of
these drugs for HP. Given the role of IFN-γ in promot-
ing granuloma formation in HP it cannot be an option
as antifibrotic treatment as it is for IPF.
Manipulation of the immune response in HP holds fu-
ture promise. In a HP experimental model mice treated
with CTLA-4Ig showed a significant decrease in the extent
of lung damage and in the number of BALF inflammatory
cells, with diminished CD4/CD8 T cell ratio. A significant
increase in the lung γδT and NKT cells was observed after
two weeks of CTLA-4Ig administration, while after 3 weeks
an increased of regulatory T cells occurred [115]. Other po-
tential targets for immune modulation in HP are Tbet,
DCs and adjuvant factors, Th17, galectin-9, Tregs and acti-
vated cytotoxic T cells.
Reparixin (Repertaxin)™ (Dompe Farmaceutici S.p.A.,
Milan, Italy Product), an inhibitor of CXCR1 and CXCR2
activation, has been shown to attenuate inflammatory
responses in various injury models [116,117] and might
prove useful in managing pulmonary fibrosis.Key-messages
1. new antigens inducing HP are described every year
for both home and work exposure
2. high index of suspicion for HP in cases with
unexplained dyspnea and frequent monitoring of
subjects at risk are essential for an early diagnosis
3. a set of complementary diagnostic tests should be
used for diagnosis and to assess severity, disease
activity and prognosis
4. environmental detection of antigen is essential for
both diagnosis and further avoidance of exposure
5. future improvement of the serological diagnosis of
HP needs a better inventory of etiologic agents with
generation of local relevant diagnostic panels, the use
of more efficient serological techniques, together
with longitudinal evaluation of exposed subjects.
6. complete antigen avoidance is the best therapeutic
measure, although very difficult to achieve in some
cases
7. systemic steroids are of value for subacute and
chronic forms of HP but do not influence long term
outcome
8. novel anti-inflammatory, immunoregulatory, and
antifibrotic treatments are urgently needed for
subacute and chronic HP
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